It has been suggested that DMN deactivation is progressively disrupted along the continuum from normal aging to MCI and AD, with increased impairment in subjects at risk for AD, such as APOE4 genotype carriers (Pihlajamäki and Sperling, 2009). The gene discussed is APOE; the disease is Alzheimer disease.